sb 203580 has been researched along with Hypercapnia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, LJ; Ma, YC; Wang, WT; Wang, YY; Ying, L; Zheng, MX | 1 |
| Armstead, WM; Cines, DB; Higazi, AA; Kiessling, JW; Riley, J | 1 |
2 other study(ies) available for sb 203580 and Hypercapnia
| Article | Year |
|---|---|
[Expression of KATP in pulmonary artery smooth muscle cells under hypoxia-hypercapnia condition and the relationship with p38 MAPK pathway].
Topics: Animals; Anisomycin; Cell Hypoxia; Cells, Cultured; Hypercapnia; Imidazoles; KATP Channels; Male; MAP Kinase Signaling System; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Pulmonary Artery; Pyridines; Rats; Rats, Sprague-Dawley; Sulfonylurea Receptors | 2014 |
PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.
Topics: Animals; Animals, Newborn; Anthracenes; Blood Pressure; Carbon Dioxide; Cardiovascular Agents; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Female; Hypercapnia; Hypotension; Hypoxia-Ischemia, Brain; Imidazoles; Injections, Intravenous; Isoproterenol; JNK Mitogen-Activated Protein Kinases; Male; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pia Mater; Protein Kinase Inhibitors; Pyridines; Swine; Time Factors; Up-Regulation; Vasodilation; Vasodilator Agents | 2010 |